• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

medinol

Medinol has first human implant of drug-eluting peripheral stent in Australia

October 7, 2024 By Sean Whooley

Medinol ChampioNIR drug-eluting stent

Medinol today announced the successful first-in-human implantation of its ChampioNIR drug-eluting peripheral stent. Dr. Gerard S. Goh and Dr. Thodur Vasudevan of the Alfred Hospital in Melbourne, Australia, completed the stent implant. The company says it introduces a “revolutionary advancement” in the mechanics, durability and drug delivery of peripheral drug-eluting stents. Tel Aviv, Israel-based Medinol […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Stents, Vascular Tagged With: medinol

FDA approves Medinol drug-eluting coronary stent

October 24, 2023 By Danielle Kirsh

Medinol-Elunir-Perl

Medinol this week announced it received FDA approval for its Elunir-Perl drug-eluting stent (DES) for the treatment of coronary artery disease. Elunir-Perl is the latest evolution in the company’s Elunir DES product portfolio. It has four radiopaque markers, two at each end of the stent, as well as a hybrid polymer-metal radiopaque catheter tip. The […]

Filed Under: Drug-Device Combinations, Stents Tagged With: medinol

Medinol stent performs just as well as Medtronic Resolute, study says

January 6, 2020 By Chris Newmarker

Medinol EluNIR drug-eluting stent

The EluNIR drug-eluting stent made by Medinol performed just as well as the Resolute Integrity or Resolute Onyx stents from Medtronic (NYSE:MDT), according to new clinical study results from an international team of researchers. The randomized clinical trial — conducted by researchers from the U.S., Israel, Canada and the Netherlands — involved 2,221 people and compared […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Stents Tagged With: Cardinal Health, medinol, Medtronic

Cordis, Medinol tout first commercial implants of Elunir drug-eluting stent in U.S.

January 11, 2018 By Sarah Faulkner

Cordis, Medinol

Cordis and Medinol announced today that the first commercial uses of the Elunir drug-eluting stent in the U.S. were performed at New York-Presbyterian Hospital/Columbia University Medical Center and the Piedmont Heart Institute in Atlanta. The Elunir stent, developed by Medinol and distributed by Cordis, features a metallic spring tip and the narrowest strut width of […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Cardinal Health, cordis, medinol

Cordis, Medinol win FDA nod for Elunir drug-eluting stent

November 30, 2017 By Sarah Faulkner

Cordis, Medinol

Cordis and Medinol announced today that the FDA approved its Elunir drug-eluting stent for the treatment of patients with narrowing or blocked coronary arteries. The stent, designed by Medinol and distributed exclusively by Cordis in the U.S., features a novel metallic spring tip and the narrowest strut width of any stent on the market in […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Stents, Vascular, Wall Street Beat Tagged With: cordis, medinol

Cordis inks exclusive distribution deal for Medinol’s coronary stent portfolio in US

October 30, 2017 By Sarah Faulkner

Cordis, Medinol

Cordis has inked an exclusive distribution deal to sell Medinol‘s coronary stents in the U.S., the company reported, adding a cobalt-chromium bare-metal stent and a drug-eluting stent to its portfolio. According to the deal, Cordis plans to start selling Medinol’s NIRxcell BMS immediately and will exclusively distribute the company’s EluNir drug-eluting stent if it wins FDA […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Pharmaceuticals, Stents, Wall Street Beat Tagged With: cordis, medinol

Medinol wins CE Mark for EluNir drug-eluting coronary stent

October 26, 2017 By Sarah Faulkner

Medinol

Medinol said today that it won CE Mark clearance for its EluNir drug-eluting stent – a device designed with a low metal footprint and an elastomeric coating. In one 958-patient clinical study, the coronary stent had a 12-month target lesion failure rate of 5.4% and a 0% rate of late stent thrombosis, proving non-inferior to […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Vascular Tagged With: medinol

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS